{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:34:44Z","timestamp":1786980884575,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["A070001"],"award-info":[{"award-number":["A070001"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10554-019-01584-y","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T01:36:27Z","timestamp":1563240987000},"page":"1745-1753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anti-inflammatory effect of statin is continuously working throughout use: a prospective three time point 18F-FDG PET\/CT imaging study"],"prefix":"10.1007","volume":"35","author":[{"given":"Min-Kyu","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Ho","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Hee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Hyun","family":"O","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3456-8705","authenticated-orcid":false,"given":"Kiyuk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"key":"1584_CR1","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425\u20131435","journal-title":"N Engl J Med"},{"key":"1584_CR2","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FAH et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195\u20132207","journal-title":"N Engl J Med"},{"key":"1584_CR3","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383\u20131389","journal-title":"Lancet"},{"key":"1584_CR4","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495\u20131504. \n                    https:\/\/doi.org\/10.1056\/NEJMoa040583","journal-title":"N Engl J Med"},{"key":"1584_CR5","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","volume":"46","author":"JG Robinson","year":"2005","unstructured":"Robinson JG, Smith B, Maheshwari N, Schrott H (2005) Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46:1855\u20131862. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2005.05.085","journal-title":"J Am Coll Cardiol"},{"key":"1584_CR6","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/S0002-9149(97)00174-4","volume":"79","author":"M Davidson","year":"1997","unstructured":"Davidson M, McKenney J, Stein E et al (1997) Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 79:1475\u20131481","journal-title":"Am J Cardiol"},{"key":"1584_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1067\/mhj.2002.128049","volume":"144","author":"AG Olsson","year":"2002","unstructured":"Olsson AG, Istad H, Luurila O et al (2002) Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 144:1044\u20131051. \n                    https:\/\/doi.org\/10.1067\/mhj.2002.128049","journal-title":"Am Heart J"},{"key":"1584_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","volume":"62","author":"A Tawakol","year":"2013","unstructured":"Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, Subramanian SS, Abdelbaky A, Rudd JHF, Farkouh ME, Nunes IO, Beals CR, Shankar SS (2013) Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation. J Am Coll Cardiol 62:909\u2013917. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2013.04.066","journal-title":"J Am Coll Cardiol"},{"key":"1584_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.nuclcard.2005.03.002","volume":"12","author":"A Tawakol","year":"2005","unstructured":"Tawakol A, Migrino RQ, Hoffmann U et al (2005) Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 12:294\u2013301. \n                    https:\/\/doi.org\/10.1016\/j.nuclcard.2005.03.002","journal-title":"J Nucl Cardiol"},{"key":"1584_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCIMAGING.108.811752","volume":"2","author":"JH Rudd","year":"2009","unstructured":"Rudd JH, Myers KS, Bansilal S et al (2009) Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography\/computed tomography imaging study. Circ Cardiovasc Imaging 2:107\u2013115. \n                    https:\/\/doi.org\/10.1161\/CIRCIMAGING.108.811752","journal-title":"Circ Cardiovasc Imaging"},{"key":"1584_CR11","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1161\/01.CIR.0000020548.60110.76","volume":"105","author":"JH Rudd","year":"2002","unstructured":"Rudd JH, Warburton EA, Fryer TD et al (2002) Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105:2708\u20132711. \n                    https:\/\/doi.org\/10.1161\/01.CIR.0000020548.60110.76","journal-title":"Circulation"},{"key":"1584_CR12","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.clinthera.2008.12.023","volume":"30","author":"J Bonnet","year":"2008","unstructured":"Bonnet J, McPherson R, Tedgui A et al (2008) Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (comparative Atorvastatin pleiotropic effects) study. Clin Ther 30:2298\u20132313. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2008.12.023","journal-title":"Clin Ther"},{"key":"1584_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/000331970605700101","volume":"57","author":"JJ Li","year":"2006","unstructured":"Li JJ, Fang CH, Qian HY, Hu WL (2006) Time course of rapid C-reactive protein reduction by pravastatin in patients with stable angina. Angiology 57:1\u20137. \n                    https:\/\/doi.org\/10.1177\/000331970605700101","journal-title":"Angiology"},{"key":"1584_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/01.CIR.104.3.249","volume":"104","author":"R Corti","year":"2001","unstructured":"Corti R, Fayad ZA, Fuster V et al (2001) Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104:249\u2013252. \n                    https:\/\/doi.org\/10.1161\/01.CIR.104.3.249","journal-title":"Circulation"},{"key":"1584_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071\u20131080. \n                    https:\/\/doi.org\/10.1001\/jama.291.9.1071","journal-title":"JAMA"},{"key":"1584_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199907083410202","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Waters D, Brown WV et al (1999) Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 341:70\u201376. \n                    https:\/\/doi.org\/10.1056\/NEJM199907083410202","journal-title":"N Engl J Med"},{"key":"1584_CR17","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","volume":"46","author":"P Libby","year":"2005","unstructured":"Libby P (2005) The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 46:1225\u20131228. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2005.07.006","journal-title":"J Am Coll Cardiol"},{"key":"1584_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D et al (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20\u201328. \n                    https:\/\/doi.org\/10.1056\/NEJMoa042378","journal-title":"N Engl J Med"},{"key":"1584_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ahj.2011.05.006","volume":"162","author":"ZA Fayad","year":"2011","unstructured":"Fayad ZA, Mani V, Woodward M et al (2011) Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography\/computed tomography. Am Heart J 162:214\u2013221. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2011.05.006","journal-title":"Am Heart J"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-019-01584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10554-019-01584-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-019-01584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T19:13:25Z","timestamp":1594754005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10554-019-01584-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1007\/s10554-019-01584-y","relation":{},"ISSN":["1569-5794","1573-0743"],"issn-type":[{"value":"1569-5794","type":"print"},{"value":"1573-0743","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,16]]},"assertion":[{"value":"17 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}